Evaluation of the Safety and Effectiveness of Calcitonin Gene-Related Peptide Antagonists in Treating Cluster Headaches: A Systematic Review and Meta-Analysis - Scorecard - MDSpire
Advertisement
Evaluation of the Safety and Effectiveness of Calcitonin Gene-Related Peptide Antagonists in Treating Cluster Headaches: A Systematic Review and Meta-Analysis
Clinical Scorecard: Evaluation of the Safety and Effectiveness of Calcitonin Gene-Related Peptide Antagonists in Treating Cluster Headaches: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Involves activation of the trigeminal-autonomic reflex and release of Calcitonin Gene-Related Peptide (CGRP), which is central to both acute and preventive therapies.
Target Population
Care Setting
Key Highlights
CGRP antagonists show potential for preventive management of CH.
Current therapies have limitations including delayed onset and monitoring requirements.
CGRP plays a central role in the pathophysiology of CH.
Further research is needed due to inconsistent findings in current studies.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Monitor for treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including specific symptoms such as cardiovascular issues or allergic reactions.
Risks
Patient & Prescribing Data
Adults with episodic or chronic cluster headache.
CGRP antagonists may reduce weekly attack frequency and improve patient-reported outcomes.
Clinical Best Practices
Utilize high-flow oxygen and non-oral triptans for acute relief.
Consider transitional therapies like prednisone when using preventive options, and educate patients on their use.
